Hospital

Capivasertib combined with fulvestrant doubled progression-free survival in patients with recurrent or progressed advanced stage HR-positive HER2-negative breast cancer compared to placebo.

Alex Mills, PharmD, BCACP, AAHIVP, discussed his presentation at the ASHP 2023 Summer Meeting.

STRONG-HF aimed to study whether rapid-dose escalation of guideline-directed heart failure medications was more beneficial than usual care.

Ambulatory care pharmacy residents play a major role in increasing both patient awareness about recommended vaccination and vaccination rates.

Denise Scarpelli, PharmD, MBA, discussed her presentation at the ASHP 2023 Summer Meeting.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.

Myths, fears, distrust, and misinformation on immunizations can keep patients from benefiting from their protective effects.

Randomized clinical trials still showed that microbiota restoration is significantly more effective than antibiotics for recurrent Clostridioides difficile infection.

Study highlights the importance of interprofessional decision-making between pharmacists and emergency department medical officers.

There are 8 million cancer survivors who may have limitations in their daily functional ability.

April Gill, chief commercial officer at Tabula Rasa HealthCare, discusses how to identify underserved patients and address social determinants of health.

Investigators from the Barts Cancer Institute discovered that AMP-activated protein kinase is an essential sensor for tumor dissemination.

People with less severe symptoms of insomnia still had a 16% increased risk of stroke compared to people with no symptoms.

Positive data from the phase 3 A DUE study demonstrated that the investigational combination therapy of macitentan 10 mg and tadalafil 40 in a single tablet improved pulmonary hemodynamics compared to the same drugs as monotherapies.

Christina Madison speaks with Sandra Leal, PharmD, fromCVS Health, about advocating for patients and how that impacts public health.

The meeting aims to bring together pharmacists to discuss solutions for responding to the rapidly evolving evidence and needs for effective implementation.

It’s time for pharmacies to take a page out of the books of hospitals and tech companies by expanding and streamlining their use of contingent labor.

The combination also reduced the risk of developing distant metastasis or death by 65% in patients with high-risk stage 3/4 melanoma.

There may be more than 200 symptoms associated with long COVID-19.

Levels of troponin were higher in people who had type 2 diabetes for a longer period than people with healthy blood levels.

Real-world metrics demonstrate that using health-system specialty pharmacies (HSSPs) means everyone wins: health systems, clinicians, and patients.

CCR5 mutation creates a challenge for HIV to infect more cells, thereby creating resistance to the virus.

Trial results support 5.4 mg/kg of trastuzumab deruxtecan as the optimal dose in individuals with HER2+ metastatic colorectal cancer.

The proposed indications for milvexian include stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.

The proportion of participants with cytomegalovirus disease was 10% with letermovir and 12% with valganciclovir.

Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

Treatment for community-acquired pneumococcal disease is dependent on patient-specific factors, whereas prevention with vaccinations is dependent on age and comorbidities.

In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.